Overall, the lack of preclinical evidence with regard to the functional role of GRB7 amplification and/or overexpression in oesophageal cancer is preventing the identification of any potential therapeutic benefits of targeting GRB7 in this disease. Here, GRB7 is linked to carcinoma of esophagus.